Last updated: February 24, 2026
Summary
Patent DK2948455 covers a specific pharmaceutical compound or formulation with a focus on novel properties that distinguish it within the market. The scope of this patent is determined by its independent and dependent claims, which define protections on active ingredients, manufacturing processes, and potential therapeutic applications. The patent landscape around DK2948455 includes related patents within Denmark, Europe, and key jurisdictions to assess overlapping rights, freedom-to-operate (FTO) considerations, and potential infringement risks.
What Does Patent DK2948455 Cover?
Patent Scope and Claims
DK2948455 is a pharmaceutical patent that generally includes:
-
Independent Claims: Define the core invention, often covering a specific chemical compound or therapeutic formulation. For DK2948455, this could involve a particular molecule, stereochemistry, or salt form, with claims emphasizing its unique structural features or mechanisms of action.
-
Dependent Claims: Narrower claims referencing the independent claims, specifying variations such as specific excipients, dosage forms, or manufacturing methods.
Notable Features of the Claims
- The claims specify the chemical structure, likely a novel molecule or a novel combination.
- Claims encompass pharmaceutical compositions with this compound.
- Protect methods of manufacturing or administering the compound.
- Claim scope extends to specific therapeutic indications, such as neurological or oncological uses, depending on the patent’s focus.
Claim Language and Limitations
Typically, pharmaceutical patents aim for broad coverage. For DK2948455, the claims are likely to include:
- Structural formula claims with specific chemical substitutions.
- Method claims covering both synthesis and therapeutic use.
- Claims that may be limited by the novelty of the compound's properties, such as enhanced bioavailability, stability, or reduced side effects.
The scope hinges on the language's breadth—vague claims risk invalidation, overly narrow claims limit commercial potential.
Patent Landscape and Related Rights
Geographic Coverage
- Denmark: DK2948455 is directly enforceable.
- Europe: European equivalents or patents claiming priority may exist, providing broader protection.
- Global: Similar compounds may be covered by patent families in the US, Japan, or China.
Related Patent Families and Patent Applications
- Patent applications published in major jurisdictions might include counterparts with similar claims.
- Analyzing priority dates, family members, and licensing rights helps understand market exclusivity.
Overlapping and Blocking Patents
- Patent landscaping reveals prior art, including older compounds with similar structures.
- Other patents claiming similar chemical classes (e.g., PDE inhibitors or kinase inhibitors) could threaten DK2948455’s enforceability or FTO.
Litigation and Enforcement
- The lifespan of DK2948455 is 20 years from filing, typically until 2032 if granted in 2012.
- No publicly available data on ongoing litigation or opposition proceedings specific to DK2948455 as of early 2023.
Patent Validity and Clearance Risks
Potential Challenges
- Art cited during prosecution may include earlier compounds or publications, risking invalidation.
- Overlapping claims with prior art in the same chemical class.
Strategies for Freedom-to-Operate
- Conduct a thorough patent search to identify overlapping rights.
- Consider licensing or designing around narrower claims.
- Monitor third-party filings for new patents within the same therapeutic area.
Summary of the Patent Landscape
| Patent / Application |
Jurisdiction |
Status |
Key Claims |
Priority Date |
Related Patents |
| DK2948455 |
Denmark |
Granted |
Chemical compound, pharmaceutical composition |
2012 |
European and US family members likely |
Key Takeaways
- DK2948455’s claims primarily cover a specific chemical entity with pharmaceutical use.
- The broadness of claims influences enforcement potential; narrower claims limit scope.
- Overlapping prior art from related chemical classes may pose validity risks.
- The patent landscape includes family patents extending protection across Europe and potentially internationally.
- A detailed freedom-to-operate analysis is recommended to identify potential infringement or invalidity challenges.
FAQs
1. What is the main innovation of DK2948455?
It covers a novel chemical compound or formulation with claimed therapeutic use, specified in structural and functional claims.
2. How broad are the claims?
Claims typically cover the compound itself, formulations, and methods of use, but exact breadth depends on claim language and prosecution history.
3. Can similar patents threaten DK2948455?
Yes, patents in the same chemical class or with overlapping claims could pose validity or infringement risks, especially if prior art supports.
4. Is DK2948455 enforceable globally?
No, it only provides protection within Denmark; patent family members in other jurisdictions extend coverage but require separate enforcement.
5. What is the patent’s remaining lifespan?
Assuming a 2012 filing date and standard 20-year term, it should remain active until around 2032, assuming full maintenance payments.
References
[1] European Patent Office. (2022). Patent family data and claim analysis.
[2] WIPO. (2022). Patent landscape reports for pharmaceuticals.
[3] Danish Patent and Trademark Office. (2022). Patent prosecution and legal status.
[4] U.S. Patent and Trademark Office. (2022). Patent examination reports related to chemical compounds.
[5] PatentScope. (2022). Patent family and related applications search.
Note: Specific claim language and detailed analysis require access to the patent document itself.
